




# Cambridge Biosciences DTP Symposium 2022


UNIVERSITY OF CAMBRIDGE




<p>9:00 - 10:10</p>	<p><b>Introduction &amp; Talks by DTP students:</b>                  Malte Lars PinckertIn - The thick of it - understanding noroviral VPg nucleotidylylation                  Craig MacKenzie - Characterisation of a novel vaccine candidate and its immune mechanism against Trypanosoma vivax infection                  Alex Guyon - Common signatures of intracellular structures formed by plant pathogens and symbionts                  Nicola Goringe - Identifying Novel Recombination QTLs Using Diverse African Arabidopsis</p>
<p>10:10 - 11:00</p>	<p><b>Break + poster (judging)</b></p>
<p>11:00 - 12:00</p>	<p><b>Talks by DTP students:</b>                  Orla Woodward - RXFP4 in the brain - a potential new target for obesity treatment                  Yizhou Yu - Mitochondrial dysfunction in Alzheimer's disease  <b>Giovanna Mallucci (Altos Labs, Principal Investigator):</b>                  Mechanisms to Medicines in Neurodegeneration</p>
<p>12:00 - 13:00</p>	<p><b>Lunch + poster</b></p>
<p>13:00 - 14:00</p>	<p><b>Talks by DTP students:</b>                  Maximilian Gantz - Mapping the fitness landscape of an imine reductase using long-read deep mutational scanning                  Lauren Maggs - Targeting autotaxin in the tumour microenvironment  <b>Simon Cook (Babraham Institute, Director):</b>                  Targeting MCL1 is synthetic lethal with BRAF and ERK1/2 pathway inhibitors in melanoma – a tale of two addictions</p>
<p>14:00 - 14:30</p>	<p><b>Break + poster (judging)</b></p>



**Oral presenters: Please come at 8:30AM to upload and test your presentation**  
**Poster presenters: Please put up your poster before 10AM**

14:30 - 16:00	<p><b>Talks by DTP students:</b></p> <p>Hannah Kiely-Collins - Developing Piperlongumine-based Targeted Protein Degraders</p> <p>Thomas King - Novel disulfide re-bridging strategy for the synthesis of antibody-drug conjugates (ADCs)</p> <p><b>Industry round table discussion:</b></p> <p>Start Codon Charles River Duke Street Bio</p> <p><b>Industry Talk</b> by Charco Neurotech</p>
16:00 - 16:30	<b>Break + poster (judging)</b>
16:30 - 17:30	<p><b>Talks by DTP students:</b></p> <p>Katriina Willgert - Transmission history of SARS-CoV-2 in humans and white-tailed deer</p> <p>Millie Race - How do we build brains? Investigating mechanical epithelial tubes that form through hollowing</p> <p><b>Jim Smith (Wellcome Trust, Director of Science)</b></p> <p>From frogs to humans—just as we'd hoped</p> 
17:30 - 19:30	<p><b>Closing remarks &amp; Awards for the best poster and talk</b></p> <p><b>Drinks &amp; canapes reception, networking session</b></p>

## POSTERS



Poster#	Name	Title
1	Adrian Murgoci	In situ study of poly (ADP-ribosylation) by solid state NMR
2	Alex Fulton	Assessing the safety of Antisense Oligonucleotides
3	Alyce McClellan	A common loss-of-function canine MC3R variant delays puberty and reduces both body weight and adiposity
4	Cameron Cole	Developing a constitutive RNA-binding ASCC3 mutant to study RQC-associated ribosomal splitting
5	Chris Godbehere	A multi-omics approach to investigate the induction and progression of toxicity in airway epithelial cells
6	Chris Micklem	Clock Coupling in Cyanobacteria
7	David O'Loughlin	Metals in Tyre Rubber as Environmental Markers
8	Deborah King	Cardiovascular contributions to cerebrovascular impairment and cognitive decline across the lifespan



# POSTERS

Poster#	Name	Title
9	Diana Voicu	EpiDRAW - a method for analysis of large-scale epigenetic data
10	Elin Falla	Modelling the effects of virus manipulation of host and vector on plant disease epidemics: why model structure matters
11	Evan Wroe	In Operando Fluorescence Microscopy and Electrochemistry of <i>Synechocystis</i> PCC6803 Biofilms
12	Filip Lastovka	Decoding bacterial virulence with high-definition ribosome profiling
13	Holly Smith	Dissociation of IP3 from IP3 receptors contributes to termination of Ca <sup>2+</sup> puffs
14	Sarah Spencer	Obesity is characterised by dysfunctional antibody responses to SARS-Cov-2 vaccination and abnormal STAT3 signalling
15	Thomas King	Novel disulfide re-bridging strategy for the synthesis of antibody-drug conjugates (ADCs)
16	Alex Guyon	Common signatures of intracellular structures formed by plant pathogens and symbionts
17	Amelia Race (Millie)	How do we build brains? Investigating mechanical forces in epithelial tubes that form through hollowing
18	Craig MacKenzie	Characterisation of a novel vaccine candidate and its immune mechanism against <i>Trypanosoma vivax</i> infection
19	Hannah Kiely-Collins	Developing Piperlongumine-based Targeted Protein Degraders
20	Katriina Willgert	Cattle movements and potential control strategies for bovine tuberculosis in an endemic setting
21	Malte Lars Pinckert	In the thick of it - understanding noroviral VPg nucleotidylation
22	Maximilian Gantz	Mapping the fitness landscape of an imine reductase using long-read deep mutational scanning
23	Orla Woodward	RXFP4 in the brain - a potential new target for obesity treatment
24	Tasmia Mirza	Establishing an Inducible System to Manipulate the Expression of Dysregulated miRNAs in Malignant Germ Cell Tumours
25	Yizhou Yu	Parp mutations protect from mitochondrial toxicity in Alzheimer's disease



# SPONSORS

## CHARCO NEUROTECH

Charco Neurotech, established in 2019 by Lucy Jung and Floyd Pierres, was founded with one ambition: to bring back smiles for people with Parkinson's. This led to their design of the CUE1, a non-invasive wearable device. The CUE1 alleviates certain Parkinson's symptoms, including stiffness and slowness of movement. It achieves this by utilising two vibration-based therapies: focused stimulation and cueing, both of which are research-validated. It also incorporates discreet medication reminders and an accompanying app, which enable the user to track their symptoms. Through these innovations, Charco Neurotech hopes to improve quality of life for all with Parkinson's.



## CHARLES RIVER

Charles River Laboratories offers Early Discovery Research to its global clients over an extensive range of therapeutic areas. Based at four sites in England, including Cambridge, Harlow, High Peak and Portishead, the Research division encompasses every scientific discipline involved in Drug Discovery, as well as multiple business functions. Offering fully integrated Drug Discovery projects, Charles River scientists are fully integrated from Target Validation through to the clinic and IND filing. Charles River - Let this be your moment.



## PAGE MEDICAL

Page Medical is a healthcare communications agency specialising in infection education. They are expert providers in their 3 key areas; e-learning, events, and consultancy. Working with the pharmaceutical industry and medical charities, Page Medical has developed and delivered their products and services in all areas of infection gaining a global reach. This year they saw their 50th open access course go live and branched out into multiday hybrid conferencing.



## START CODON

Start Codon is a venture capital investor and venture builder based in Cambridge, England that support aspiring entrepreneurs to spin out and/or help in the development and commercialisation of their disruptive innovations. Start Codon invests a minimum of £250,000 into each of its portfolio companies in addition to enrolling them into its unique and innovative venture building programme. Through this, Start Codon provides a combination of access to a dedicated and experienced team, access and support from mentors who are leaders in their field, and the ability to tap into an extensive network of investors, pharma and biotech partners, commercial partners and collaborators.

